tradingkey.logo
tradingkey.logo
Search

LeonaBio Ord Shs

LONA
Add to Watchlist
3.470USD
-0.260-6.97%
Close 11-13 16:00(ET)
32.69MMarket Cap
LossP/E TTM

About LeonaBio Ord Shs Company

LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.

LeonaBio Ord Shs Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of LeonaBio Ord Shs

Name
Name/Position
Position
Shareholding
Change
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
15.89K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%

FAQs

Who are the top five shareholders of LeonaBio Ord Shs?

The top five shareholders of LeonaBio Ord Shs are: Dr. Mark James Litton, Ph.D.

How many institutions hold shares of LeonaBio Ord Shs (LONA)?

As of 2026Q1, 120 institutions hold shares of LeonaBio Ord Shs, with a combined market value of approximately 6.66M, accounting for 70.97% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2319889.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.